Apyx Medical Story

<div class='circular--portrait' style='background:#FF6600;color: #FFFAFA;font-size:4em;'>AM</div>
APYX -- USA Stock  

USD 4.69  0.24  4.87%

Apyx Medical is scheduled to announce its earnings today. The next earnings report is expected on the 9th of November 2020. While many of us are getting excited about healthcare space, we are going to break down the feasibility of acquiring Apyx Medical. We will evaluate if Apyx Medical shares are reasonably priced given the current economic outlook.
Published over a month ago
View all stories for Apyx Medical | View All Stories
Our current take on Apyx Medical (NASDAQ:APYX) analyst consensus
Apyx Medical is UNDERVALUED at 5.90 per share with modest projections ahead. We provide trade advice to complement the prevailing expert consensus on Apyx Medical. Our dynamic recommendation engine uses a multidimensional algorithm to analyze the company's potential to grow using all technical and fundamental data available at the time.
What is the right price you would pay to acquire a share of Apyx Medical? For most investors, it would be the price that gives them a wide margin of safety to have minimal downside risk. In other words, most investors are always looking for undervalued stocks. Even if the future performance is not entirely as expected, the loss of holding it is minimized, and the downside risk is negated. Please read more on our stock advisor page.

What is happening with Apyx Medical this year

Annual and quarterly reports issued by Apyx Medical are formal financial statements that are published yearly and quarterly and sent to Apyx Medical stockholders. The reports show and break down the current year's ongoing operations and discuss plans for the upcoming year. Annual reports have been a requirement from the Securities and Exchange Commission (SEC) for businesses owned by the public since 1934. Companies such as Apyx Medical often view their annual report as an effective marketing tool to disseminate their perspective on company future earnings or innovations. With this in mind, many companies devote large sums of money to making their reports attractive and informative. In such instances, the annual report becomes a forum through which a company can communicate to the general public any number of topics that may or may not be directly related to the actual data published in the reports.

How Apyx Medical utilizes its cash?

To perform a cash flow analysis of Apyx Medical, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Apyx Medical is receiving and how much cash it distributes out in a given period. The Apyx Medical cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities. Apyx Medical Net Cash Flow from Operations is fairly stable at the moment as compared to the past year. Apyx Medical reported Net Cash Flow from Operations of (18.48 Million) in 2019

Acquisition by Minnie BaylorHenry of 17000 shares of Apyx Medical subject to Rule 16b-3

Legal trades by Apyx Medical insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
Apyx Medical insider trading alert for grant of stock option (option to buy) by Minnie BaylorHenry, the corporate stakeholder, on 10th of August 2020. This event was filed by Apyx Medical Corp with SEC on 2020-08-10. Statement of changes in beneficial ownership - SEC Form 4 [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

Is Apyx Medical a risky opportunity?

Let's check the volatility. Apyx Medical is looking slightly risky at this time. Whether you invest your money or manage your clients' funds, remember that it is easy to forget that behind Apyx Medical (NASDAQ:APYX) stock is an actual business venture. So, do not let stock picking become an abstract concept by ignoring the elementary risk calculations. acquiring a share of an Apyx Medical stock makes you a part-owner of that company.

Apyx Medical Current Consensus

Here is the current trade recommendation based on an ongoing consensus estimate among financial analysis covering Apyx Medical. The Apyx Medical consensus assessment is calculated by taking the average estimates from all of the analysts covering Apyx Medical

Strong Buy
1
Buy
1
Hold
1
Strong Buy133.33
Buy133.33
Hold133.33
Sell00.0
Strong Sell00.0

Can Apyx Medical build up on the current rise?

The potential upside is down to 16.94 as of today. Apyx Medical is displaying above-average volatility over the selected time horizon. Investors should scrutinize Apyx Medical independently to ensure intended market timing strategies are aligned with expectations about Apyx Medical volatility.

Our Final Take On Apyx Medical

While some companies within the medical devices industry are still a little expensive, even after the recent corrections, Apyx Medical may offer a potential longer-term growth to investors. The inconsistency in the assessment between current Apyx Medical valuation and our trade advice on Apyx Medical is due to the recent market swings and your selection of investing horizon. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Apyx Medical.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Vlad Skutelnik do not own shares of Apyx Medical. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com